What price range applied to Lauren Riker’s Pacira (PCRX) share sale?

The filing explains that the 4,000 shares sold on February 2, 2026 were executed in multiple trades at prices ranging from $20.35 to $21.28. The reported $20.81 figure in the Form 4 is a weighted average price across those individual transactions.

Pacira BioSciences (PCRX) finance SVP Riker sells 4,000 shares

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Pacira BioSciences, Inc. Senior Vice President of Finance Lauren Riker reported routine equity transactions in company stock. On January 30, 2026, 2,751 shares of common stock were withheld by Pacira to cover tax obligations upon vesting of a restricted stock unit award at $20.54 per share. On February 2, 2026, Riker sold 4,000 shares of common stock at a weighted average price of $20.81 per share, executed under a pre-established Rule 10b5-1 trading plan. After these transactions, Riker directly beneficially owned about 52,313.242 shares of Pacira common stock.

Insider Trade Summary

Net Seller: 4,000 shares ($83,240)

Net Sell 2 txns

Insider RIKER LAUREN

Role Senior Vice President, Finance

Sold 4,000 shs ($83K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,000	$20.81	$83K
Tax Withholding	Common Stock	2,751	$20.54	$57K

Holdings After Transaction: Common Stock — 52,313.242 shares (Direct)

Footnotes (1)

Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.35 to $21.28, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3.

Form 4 Insider Transactions: What Each Field Means →

02/03/2026 - 06:24 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RIKER LAUREN

(Last)

(First)

(Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE

94005

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Senior Vice President, Finance

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/30/2026		F		2,751⁽¹⁾	D	$20.54	56,313.242	D
Common Stock	02/02/2026		S		4,000⁽²⁾	D	$20.81⁽³⁾	52,313.242	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.35 to $21.28, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Pacira BioSciences (PCRX) report for Lauren Riker?

Pacira BioSciences reported that Senior Vice President, Finance Lauren Riker had 2,751 shares withheld for taxes upon RSU vesting and sold 4,000 common shares. The transactions occurred on January 30 and February 2, 2026, and were disclosed in a Form 4 filing.

How many Pacira (PCRX) shares did Lauren Riker sell and at what price?

Lauren Riker sold 4,000 shares of Pacira common stock at a weighted average price of $20.81 per share. The filing notes these were multiple trades between $20.35 and $21.28, reported as a single weighted-average line in the Form 4.

Was the Pacira (PCRX) insider sale by Lauren Riker under a Rule 10b5-1 plan?

Yes. The Form 4 states that the 4,000-share sale on February 2, 2026 was executed under a pre-arranged Rule 10b5-1 trading plan. Such plans allow insiders to schedule trades in advance, helping separate personal trading from day-to-day corporate developments.

How many Pacira (PCRX) shares does Lauren Riker own after these transactions?

After the reported transactions, Lauren Riker beneficially owned 52,313.242 Pacira common shares directly. This figure reflects the effect of both the 2,751 shares withheld for taxes and the 4,000 shares sold, as disclosed in the Form 4 table totals.

Why were 2,751 Pacira (PCRX) shares withheld from Lauren Riker?

The 2,751 shares were withheld by Pacira to satisfy tax withholding obligations upon the vesting of a restricted stock unit award. Instead of paying cash taxes, a portion of the vested shares was retained by the company, a common method of handling RSU-related taxes.